Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer-Reference-Cited by-同舟云学术

Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer

Published:2020-12-09 Issue:1 Volume:21 Page:81-92
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

El Hachem Georges¹,Gombos Andrea²,Awada Ahmad²^ORCID

Affiliation:

1. Hematologist and Medical Oncologist, Saint George Hospital University Medical Center, University of Balamand, Beirut, Lebanon

2. Medical Oncologist, Oncology Medicine Department, Institut Jules Bordet, Université Libre De Bruxelles, Brussels, Belgium

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1834385

Reference59 articles.

1. Cancer statistics, 2019

2. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

3. Breast cancer

4. Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer

5. Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance;Frontiers in Immunology;2024-08-05

2. Histone deacetylases facilitate Th17-cell differentiation and pathogenicity in autoimmune uveitis via CDK6/ID2 axis;Journal of Advanced Research;2024-08

3. The importance of protein domain mutations in cancer therapy;Heliyon;2024-03

4. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases;Journal of Medicinal Chemistry;2023-03-06

5. Theranostics platform of Abemaciclib using magnetite@silica@chitosan nanocomposite;International Journal of Biological Macromolecules;2022-11